The findings of this study demonstrated a significant reduction in the expression levels of TNF-α, IL-1β, and IL-6 in MS-CSF treated astrocytes compared to healthy CSF treated and untreated groups. The gene discussed is IL1B; the disease is myeloid sarcoma.